ESH Video

2nd How to Diagnose and Treat: Acute Leukaemia

2nd How to Diagnose and Treat: Acute Leukaemia
March 13 - March 15, 2020 - Budapest, Hungary
Chairs : Hervé Dombret, Arnold Ganser, Jorge Sierra, Wendy Stock


ESH 2nd How to Diagnose and Treat:
Acute Leukaemia
March 13-15, 2020 – Budapest, Hungary
Chairs: Hervé Dombret, Arnold Ganser, Jorge Sierra, Wendy Stock

Programme Summary

European School of Haematology (ESH) How to Diagnose and Treat meetings are disease-specific meetings that address state-of-the-art diagnostic and clinical management on the basis of presentation, analysis and discussion of real clinical cases. One major objective is to promote interaction between the speakers and participants.

Novel and still evolving insights into the biology and diagnosis of acute leukaemias, including acute myeloid leukaemias (AMLs) and acute lymphoblastic leukaemias (ALL), is offering new therapeutic options with recent drug approvals to treat newly-diagnosed as well as relapsed/refractory disease.

The programme of this “2nd How to Diagnose and Treat: Acute Leukaemia” meeting will deal with integration of genomic analysis and cutting-edge technics in routine diagnosis, gene mutation-based therapies and new standard treatment algorithms, allogeneic haematopoietic stem cell (HSCT) transplantation and innovative immunotherapies, as well as diagnosis and management of rare acute leukaemia subtypes.

Posters and Brief Oral Communications:

Registered participants are invited to submit their Biology and Clinical abstracts, and Clinical Cases. Selected abstracts will be presented as posters; selected Clinical Cases will be presented as brief oral communications or posters.

Call for Abstracts and Clinical Cases: extended deadline January 19, 2020


This meeting will be valuable for you if you are looking for:

  • A cutting-edge scientific programme – from basic science to clinical and therapeutic applications and perspectives
  • Multiple opportunities for scientific interaction with an international faculty of distinguished experts
  • An emphasis on critical discussion

 The meeting will provide clinicians and biologists with state-of-the-art recommendations regarding patient care and insights into controversies and new therapeutic perspectives in the field.

This meeting will be of interest to:

  • Senior biologists and clinicians, including experts in the field (MD, PhD, MD-PhD)
  • Junior biologists and clinicians (MD, PhD) 
  • Clinical residents still in-training
  • Allied health care professionals

Learning objectives:

  • Learn about the modern sets of diagnosis tests needed to optimally manage patients with AML and ALL
  • Review and hierarchize the new treatment standards that available to AML and ALL patients for front-line and for salvage therapy
  • Understand the value and role of leukaemic stem cell targeting and measurable residual disease (MRD) levels to stratify acute leukaemia therapy
  • Gain insight into emerging mechanisms associated with clinical resistance and leukaemia escape
  • Understand the effects and place of new immunotherapies with respect to standard or new HSCT procedures

Topics :

  • Rare subsets of acute leukaemia
  • Tracking leukaemic stem cells (LSCs)
  • Routing diagnosis gene expression and mutational profiling
  • Addition of a 3rd agent to frontline 7+3
  • Allogeneic hematopoietic stem cell transplantation (HSCT)
  • Immunotherapy for acute leukaemia

The programme will include:

  • Plenary Sessions
  • Interactive Case Presentations
  • Roundtables
  • Panel Discussions
  • Debates
  • Poster Presentations
  • Voting boxes

Abstract submission






Friday, 13th March from 13:30 to 14:30:
T-cell engaging immuno-oncology therapy in ALL: from clinical trials to real-world evidence
SPEAKERS: Nicolas Boissel (Paris), Christina Peters (Vienna)
This symposium is organised and funded by Amgen

Saturday, 14th March from 13:10 to 14:10:
AML treatment: Where are we heading? 
CHAIR: Andrew Wei (Melbourne)
SPEAKERS: Konstanze Döhner (Ulm), Gail Roboz (New York)
This symposium is organized and funded by Celgene. A Bristol-Myers Squibb company

Saturday, 14th March from 17:20 to 18:20:
AML: Bringing precision medicine and MRD into clinical strategies
CHAIR: Jorge Sierra (Barcelona)
SPEAKERS: Lionel Adès (Paris), Lars Bullinger (Berlin), Jorge Sierra (Barcelona)
This symposium is organised and funded by Novartis

Sunday, 15th March from 08:30 to 09:30:
Waking up to a new decade of individualized treatment for AML
CHAIR: Jorge Sierra (Barcelona)
SPEAKERS: Jacqueline Cloos (The Netherlands), Pau Montesinos (Valencia), Andrew Wei (Melbourne)
This symposium is organised and funded by Astellas


Until January 12th, 2020, you may benefit from a special rate at the Marriott Budapest Hotel, where the conference will take place by clicking on the following link:

Book your group rate for Acute Leukaemia 2020


Budapest Marriott Hotel

Apaczai Csere Janos u. 4.,

Budapest  1052



This venue is not classified by any star rating.
Please click HERE to see the attestation certifying that this hotel is unclassified.

Corporate partners

With the support of*



Major Conference Partners




Level 2 Conference Partners


Supporting Partner 



*ESH conference programmes are developed in strict scientific independence
with no input from corporate sponsors.


ESH Scholarship Fund is a multi-sponsored project designed to support access to new biological and clinical data in the context of lifelong learning in Haematology.
– ESH independently ensures all scientific peer review and selection procedures.
– ESH is also independently responsible for all administrative aspects of the Fund. 

Scholarships and travel grants are available for this conference.
You are eligible to apply if you are:

– a fully-trained clinical haematologist or a clinical resident working in Europe.
Click here for more information and to download the Application form.
Extended deadline for applications: January 19, 2020

For more information Please contact:



Educational Grants


The registration fee for the “2nd How to Diagnose and Treat Acute Leukaemia” conference is:
– 600€  for fully trained
– 300€ for in-training
– 300€ for Allied Health Professional

A proof will be requested to confirm your status.

This fee includes:
Your seat in the Conference Room
The conference materials,
Welcome cocktail, luncheons, refreshments throughout the conference.

Your seat in the conference will be definitively reserved upon receipt of your fee.


How to proceed :
Please make sure that your Internet browser (Firefox, Safari, Google Chrome…) is up-to-date. Using an old version may prevent you from visualising the full website content.

A) For Individual Registration:
1. Click on REGISTER HERE at the bottom of the page
3. Create an account and complete the registration form. It is very important to use the email of the participant in the form.
4. Proceed with the payment.

B) For Group Registration (More than one person):
1. Click on REGISTER HERE at the bottom of the page
3. Create an account and fill in the complete details for each person that you would like to register (Use the personal email address of each participant you are registering, failure to do so will prohibit you from completing the registrations.)
4. Proceed with payment.

Cancellation policy of registration fee
In case of cancellation, up until two months prior to the beginning of the meeting, your registration fee will be reimbursed in full (less bank charges). If the cancellation is notified between 60 to 15 days prior to the beginning of the meeting, 50% of the registration fee will be reimbursed (less bank charges). Cancellations notified 15 days before the meeting will not be reimbursed. For credit card payments please register on-line first. Please note that ESH can accept VISA, MASTERCARD/EUROCARD, AMEX and CB.